Nov 13 (Reuters) - Metsera (MTSR.O) shareholders on Thursday approved Pfizer’s (PFE.N) takeover offer worth up to $10 billion, as per preliminary count, allowing the U.S. pharmaceutical giant to gain a foothold in the lucrative obesity treatment market after a fierce bidding war with Wegovy-maker Novo Nordisk (NOVOb.CO) .
The approval paves the way for Pfizer to diversify beyond its shrinking COVID-19 portfolio, navigate looming patent expirations, and tap into the booming market for weight-loss drugs that analysts estimate could be worth $150 billion annually by the end of the decade.
Metsera’s board had unanimously recommended shareholders to approve the amended Pfizer merger agreement, which
valued
the biotech at up to $86.25 per share, including an upfront payment of $65.60 per share in cash and up to $20.65 per share additionally, contingent on the success of its pipeline of drugs.

MTSR

Metsera shareholders have approved Pfizer's acquisition offer worth up to $10 billion. This move allows Pfizer to enter the obesity treatment market and diversify beyond its COVID-19 portfolio. The deal values Metsera at up to $86.25 per share, with an upfront payment of $65.60 per share in cash and up to $20.65 per share contingent on drug pipeline success.

- Metsera shareholders approved Pfizer's takeover offer valued at up to $10 billion, enhancing Pfizer's position in the obesity treatment market.  
- This acquisition allows Pfizer to diversify from its declining COVID-19 portfolio and address upcoming patent expirations while entering a market projected to reach $150 billion annually by the decade's end.  
- The deal includes a valuation of up to $86.25 per share, with an upfront cash payment of $65.60 and additional contingent payments based on drug pipeline success.

Metsera shareholders vote for up to $10 billion acquisition by Pfizer